Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gypenoside L is a dammarane-type saponin isolated from the herbaceous vine *Gynostemma pentaphyllum* (Jiaogulan). It has been investigated for its anti-proliferative and anti-tumor properties, particularly in preclinical models of human liver and esophageal cancer. The compound acts by inducing cellular senescence and S-phase cell cycle arrest, rather than immediate apoptosis. This effect is mediated through the activation of the p38 and ERK mitogen-activated protein kinase (MAPK) pathways, as well as the NF-κB signaling pathway, which subsequently upregulates the senescence-related cyclin-dependent kinase inhibitors p21 and p27. Preclinical studies also suggest that gypenoside L can act as a chemosensitizer, enhancing the cytotoxicity of standard chemotherapeutic agents such as 5-fluorouracil and cisplatin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gypenoside L.